Partnership 2024 - present. In 2024, BEC supported the expansion of a rare disease hematology sales organization, placing 3 Regional Business Directors and 25 Hematology Sales Representatives. In 2026, our partnership expanded to support a sickle cell disease launch, building teams across sales, Medical Affairs, market access, patient services, and clinical education.
Partnership March 2026 - present. Supported Alnylam's expansion of its RNAi therapeutics field organization by placing 135 professionals across commercial, medical affairs, market access, reimbursement, and patient support functions. Key placements included Business Account Executives, Strategic Account Directors, Federal Account Directors, Medical Science Liaisons, Field Reimbursement leaders, Patient Education Liaisons, and Site of Care leadership. This team was built to support disease-state education, patient access initiatives, provider engagement, and strategic stakeholder partnerships across the rare disease landscape. Primary Focus: Rare Disease | RNAi Therapeutics
Partnership 2022 to present In 2022, BEC supported the expansion of Travere Therapeutics’ rare disease nephrology team in preparation for the launch of sparsentan, a treatment for IgA nephropathy (IgAN). We placed 6 Zone Business Directors, 56 Clinical Account Managers, 1 Area Director of Medical Science Liaisons, and 7 Senior Medical Science Liaisons. Our partnership continues across Travere’s commercial, market access, and Medical Affairs teams, with searches for Clinical Account Managers, Access & Reimbursement Directors, Access & Reimbursement Managers, Thought Leader Liaisons, and Medical Science Liaisons. Primary focus isRare DiseaseinNephrology/Kidney.
2020/2021 Expansion of Anti-infective Institutional Sales Force Placed 23+ Key Account Managers and additional KAMLeaders, Associate Director of Sales Operations and Sr. Manager of Training. 2025 Retained for the newly created Primary Care Division. Placed VP/Head of Sales, 2 National Regional Sales Directors (2nd Line leadership.) 2025 Retained for the newly created LTC Division. Placed 2 National Area Business Leaders (1st Line Leadership.) Primary focus to develop andcommercialize pharmaceuticalproducts to treat areas of infectious diseases and pain, as well as otherareas of high medical need,including chronic liver disease.
Partnership 2022 - present. Involved with National Expansion Roles for Prostate Cancer / Diagnostic PyLARIFY Radioisotope which included placement of 3 Leadership roles and 30+ Prostate Cancer focused front-line Field Sales force roles.
Partnership since 2013 with 4 Phases of Expansion Placed Over 190 Sales Representatives Primary focus on ADHD and Parkinson’s Disease
Takeda (Osaka, Japan and Cambridge, MA based 240+ year old Global Pharmaceutical company with core therapeutics in gastrointestinal/inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines). Retained Partner from 2021 – Present. Involved with 2022 National Expansion Roles for Rare Disease Franchise. Successfully placed 20+ Territory Business Managers for Plasma Derivative Therapies/Rare Disease/Neuromuscular Expansion. Primary focus is Neurology and Movement Disorders for (MMN) Multi Motor Neuropathy and upcoming indication HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Partnership 2020 to Present Placed Placed 6 Sales Reps and 1 Oncology Key Account Director. Oncology Division Primary focus is innovating with next-generation therapies, combinations and technologies to help transform how cancer is treated.
Partnership 2021 - Present. Placements for National Expansion of Commercial Team Roles: Two Strategic Account Director – IDNs (East & West) One Senior Director - Strategic Accounts-GPOs, Senior Director – Channel Strategy & Distribution Operations. Successful placement for National Expansion of Leadership Role: Senior Director – National Sales for PNH Division
Partnership 2018 to Present 2019/2020 Expansion of Sales Force Roles recruited for: Director of Commercial Effectiveness & Training, 2 Long Term Care Area Sales Directors (2nd Line), 4 Neuroscience Area Director roles (2nd Line), 4+ Market Development, Manger roles (Key Accounts/Market Access/KOL), 7 Long Term Care RSMs (1st Line) and 18 Neuroscience RSMs (1st Line)
1999 - Present. Placed 100+ Territory Sales Representative positions for this Leading Medical Plastic Surgery and General Surgery Device client on a National basis.
Partnership 2015 to Present Placing Manager of Market Development, VP of Sales (West), National Sales Training Director, and 30+ sales representatives A diagnostic solutions company focusing to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease
Partnership 1995 to Present. Placed 200+ including Oncology Sales Representatives, Regional Sales Managers, District Sales Managers, Institutional Sales Representatives & Corporate Account Manager (Key Accounts) roles in Oncology, Nephrology, Cardiology, etc.
Partnership 1/2020 to Present. Roles recruited for: 15 Hospital Sales Executives focused on Cardinal Health Brand Categories (Incontinence, Exam Gloves, Infection Control, Wound Care, and Fluid Management), Performance Plus partnerships and services portfolio at assigned Hospitals, IDNs and Regional Health Systems.
Partnership 1998 to Present. Placed 200+ Sales Representatives and Leaders within Oncology, Hospital/Institutional, Rheumatology, Neurology, Metabolism, Immunology and Ophthalmology sale and leadership positions.
Hundreds of Executive VP, VP, Director, Strategic Accounts, Field Sales, and Clinical positions filled within BD/Carefusion/Pyxis/Alaris/Medmined since the commencement of our relationship in 1979.
Partnership 2013 - 2016. Placed their Sales Management Leadership team (over 14 individuals which included 3 Key Account Executives and 11 Area Sales Managers). Our firm has placed over 70+ Sales Representatives for the launch of Cologuard (Diagnostic for Colo-Rectal Cancer) 2013- 2017
The Client A specialty life sciences company preparing for nationwide commercial expansion across cardiology, nuclear oncology, and prostate cancer i...
A long-standing client in the rare disease space partnered with BEC Search to support a commercial launch buildout. Having previously collaborated on ...
Case Study: Expanding a Rare Disease Hematology Team at Speed and Scale The Client A leading rare disease hematology company preparing for growth i...
How BEC selected the 20 Neuromuscular Territory Business Managers that would elevate Takeda’s sales performance and outreach. Introduction Companies...
4449 Easton Way, Suite 130
Columbus, Ohio 43219
(614) 825-6215
